Afinitor and Psoriasis - a phase IV clinical study of FDA data
Summary:
Psoriasis is reported as a side effect among people who take Afinitor (everolimus), especially for people who are female, 50-59 old, have been taking the drug for 6 - 12 months also take Sandostatin, and have Carcinoid tumor.
The phase IV clinical study analyzes which people have Psoriasis when taking Afinitor. It is created by eHealthMe based on reports of 41,609 people who have side effects when taking Afinitor from the FDA, and is updated regularly.
What is Afinitor?
Afinitor has active ingredients of everolimus. It is often used in breast cancer metastatic. eHealthMe is studying from 41,680 Afinitor users. Check the latest studies of Afinitor.
What is Psoriasis?
Psoriasis (immune-mediated disease that affects the skin) is found to be associated with 1,474 drugs and 1,695 conditions by eHealthMe. Check the latest studies of Psoriasis.
eHealthMe: drug outcomes in the real world
eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.
41,609 people reported to have side effects when taking Afinitor.
Among them, 52 people (0.12%) have Psoriasis.

Among these 52 people:
How long have people been on Afinitor when they have Psoriasis? *
- < 1 month: 30.77 %
- 1 - 6 months: 23.08 %
- 6 - 12 months: 46.15 %
- 1 - 2 years: 0.0 %
- 2 - 5 years: 0.0 %
- 5 - 10 years: 0.0 %
- 10+ years: 0.0 %
What is the gender of people who have Psoriasis when taking Afinitor? *
- female: 62.75 %
- male: 37.25 %
What is the age of people who have Psoriasis when taking Afinitor? *
- 0-1: 0.0 %
- 2-9: 2.33 %
- 10-19: 2.33 %
- 20-29: 0.0 %
- 30-39: 2.33 %
- 40-49: 13.95 %
- 50-59: 48.84 %
- 60+: 30.23 %
What are other drugs people take besides Afinitor? *
- Synthroid: 17 people, 32.69%
- Sandostatin: 17 people, 32.69%
- Pantoprazole: 15 people, 28.85%
- Amlodipine: 11 people, 21.15%
- Aldactone: 6 people, 11.54%
- Innohep: 6 people, 11.54%
- Sutent: 6 people, 11.54%
- Opdivo: 6 people, 11.54%
- Cabometyx: 5 people, 9.62%
- Enbrel: 4 people, 7.69%
What are other side effects people have besides Psoriasis? *
- Acne (skin problems that cause pimples): 27 people, 51.92%
- Malignant Neoplasm Progression (cancer tumour came back): 26 people, 50.00%
- Weakness: 24 people, 46.15%
- Fatigue (feeling of tiredness): 24 people, 46.15%
- Dry Skin: 22 people, 42.31%
- Oedema Peripheral (superficial swelling): 21 people, 40.38%
- Drowsiness: 20 people, 38.46%
- Diarrhea: 20 people, 38.46%
- Hyperglycemia (high blood sugar): 19 people, 36.54%
- Muscle Aches (muscle pain): 19 people, 36.54%
What are the existing conditions these people have? *
- Carcinoid Tumor: 18 people, 34.62%
- Renal Cell Carcinoma (a kidney cancer): 8 people, 15.38%
- High Blood Pressure: 5 people, 9.62%
- Heart Disease: 3 people, 5.77%
- Neuroendocrine Tumor: 3 people, 5.77%
- Tuberous Sclerosis (a rare genetic disease that causes benign tumours to grow in the brain and other organs): 1 person, 1.92%
- Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 1 person, 1.92%
- Astrocytoma (tumour of the brain that originate in a particular kind of glial-cells): 1 person, 1.92%
- Breast Cancer Stage Iv: 1 person, 1.92%
- Carcinoid Tumor Pulmonary: 1 person, 1.92%
* Approximation only. Some reports may have incomplete information.
Do you take Afinitor and have Psoriasis?
- Check whether Psoriasis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Afinitor:
- Afinitor (41,680 reports)
Psoriasis treatments and more:
- Psoriasis (508,164 reports)
How severe was Psoriasis and when was it recovered:
Expand to all the drugs that have ingredients of everolimus:
- Psoriasis and drugs with ingredients of everolimus (62 reports)
Sub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Afinitor:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Psoriasis:
- Psoriasis (1,474 drugs)
Browse all the conditions that are associated with Psoriasis:
- Psoriasis (1,695 conditions)
Related publications that referenced our studies
- Mohagheghi MA, Omranipur R, Ensani F, Ghannadan A, Shahriaran S, Samiee F, Sedighi Z, "A Case of Advanced Unicentric Retroperitoneal Castleman's Disease, Associated With Psoriasis", Acta Medica Iranica, 2017 May .
- Chiriac A, Brzezinski P, Stolnicu S, Podoleanu C, Moldovan C, Molnar C, Taranu T, "Eosinophilia–A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis", Journal of Dermatological Treatment, 2016 Mar .
- Malisiewicz B, Murer C, Schmid JP, French LE, Schmid-Grendelmeier P, Navarini AA, "Eosinophilia during psoriasis treatment with TNF antagonists", Dermatology, 2013 Jan .
- Mohagheghi MA, Omranipur R, Ensani F, Ghannadan A, Shahriaran S, Samiee F, Sedighi Z, "A Case of Advanced Unicentric Retroperitoneal Castleman's Disease, Associated With Psoriasis", Acta Medica Iranica, 2017 May .
- Chiriac A, Brzezinski P, Stolnicu S, Podoleanu C, Moldovan C, Molnar C, Taranu T, "Eosinophilia–A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis", Journal of Dermatological Treatment, 2016 Mar .
- Malisiewicz B, Murer C, Schmid JP, French LE, Schmid-Grendelmeier P, Navarini AA, "Eosinophilia during psoriasis treatment with TNF antagonists", Dermatology, 2013 Jan .
How the study uses the data?
The study uses data from the FDA. It is based on everolimus (the active ingredients of Afinitor) and Afinitor (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Appetite Decreased and drugs of ingredients of meprobamate - a second ago
- Ibu and Stiff Lung for Women aged 20-29 - a second ago
- Appetite - Decreased and drugs of ingredients of meprobamate - a second ago
- Ibu and Shock Lung for Women aged 20-29 - 2 seconds ago
- Ibu and Non-Cardiogenic Pulmonary Edema for Women aged 20-29 - 2 seconds ago
- Ibu and Increased-Permeability Pulmonary Edema for Women aged 20-29 - 2 seconds ago
- Could Thyrogen cause Headache? - 2 seconds ago
- Ibu and Adult Respiratory Distress Syndrome for Women aged 20-29 - 3 seconds ago
- Ibu and Acute Respiratory Distress Syndrome for Women aged 20-29 - 3 seconds ago
- Ibu and Acute Lung Injury for Women aged 20-29 - 3 seconds ago